Frazis Capital Podcast
Michael Frazis describes his investment company’s strategy that involves a 30-40 year view, not panicking and diverting the approach during dips and rallies.
Michael Frazis attempts to understand the FDA’s decision to approve Biogen’s aducanumab for Alzheimer’s and the possible ramifications.
Timestamps 0:32 – Our fast-growing portfolio companies. 2:21 – Frazis life sciences strategy update. 5:18 – RNAi Biology
New Episodes Weekly
Live Every Thursday @ 9am
This Weeks Guest.
Robert Stretch, MD
Signup for Frazis Insights
Get monthly shareouts from the Frazis team, keep up to date on perspectives, interviews, features, spaces and more.